Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$8.23
$0.23(2.80%)
At close: 4:00 PM EST
$8.23
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$5.41 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)16.10K
Market Cap
$5.87M
Enterprise Value$5.05M
Total Cash (Recent Filing)$937.50K
Total Debt (Recent Filing)$102.27K
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue68.04
Enterprise Value/Gross Profit-29.65
Enterprise Value/Ebitda-0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Partnered Upside With IndiviorA large, structured collaboration with Indivior creates meaningful non-dilutive upside via milestones and royalties, shifting execution and late‑stage costs to a commercial partner. This materially de‑risks parts of the pipeline and strengthens lasting monetization pathways and partnership credibility.
Differentiated GABAB PAM ProfileRobust, cross‑species efficacy with a wide safety margin and favorable tolerability versus comparators indicates true differentiation. Such durable pharmacologic advantages increase probability of clinical success, improve licensing leverage, and support longer‑term commercial interest from partners or acquirers.
Low Financial LeverageVery low debt reduces solvency risk and preserves strategic flexibility to pursue partnerships, licensing, or contingent financings. Conservatively financed balance sheets afford surviving development-stage biotech optionality over multiple quarters without debt service constraints, supporting long-term strategy execution.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals the business cannot self‑fund development and must repeatedly access external capital. Over 2–6 months this raises dilution and execution risk on unpartnered programs and limits the company's ability to advance multiple programs concurrently.
Thin Near‑term Cash RunwayReported cash levels and management guidance imply runway that does not cover key IND‑enabling and clinical starts without new financing or partnering. This structural funding gap can delay development timelines, reduce negotiating leverage with partners, and force asset monetization or dilutive raises.
Rising Equity‑method LossesGrowing share of losses from Neurosterix increases reported net losses and compresses equity, straining reported profitability and potentially restricting capital allocation. Continued equity‑method deficits can force strategic choices (monetization, dilution) that materially affect long‑term value capture.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $5.41 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $5.87M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 51 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
ADXN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents meaningful scientific and preclinical progress — notably strong antitussive data for the GABAB PAM (Compound A), clear rationale and readiness for dipraglurant in post-stroke/TBI recovery, a value-creating Neurosterix spinout nearing Phase 1 readout, and a partnered program with material milestone upside via Indivior. However, these operational and pipeline positives are tempered by a constrained cash position, increasing reported losses driven by the equity-method share of Neurosterix, and the explicit need for additional financing or partnering to start IND-enabling studies and advance unpartnered programs. Overall, the company shows strong R&D momentum but meaningful near-term financing risk.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---